Macular Pigment in Aging and Disease
衰老和疾病中的黄斑色素
基本信息
- 批准号:9274977
- 负责人:
- 金额:$ 96.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-06-01 至 2020-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptedAgeAge related macular degenerationAge-YearsAgingApoptosisBeta CaroteneBlindnessCarotenoidsChronic DiseaseClinicalCohort StudiesCross-Sectional StudiesDataDevelopmentDevicesDietDietary CarotenoidDiseaseEyeEye diseasesFollow-Up StudiesFood SupplementsFundusGuidelinesIncidenceIndividualInflammationIntakeInvestigationKnowledgeLeadLightLongitudinal StudiesLuteinMeasuresNerve DegenerationNeural RetinaNeuronsNutritionalOptic DiskOptical Coherence TomographyOpticsOxidative StressParticipantPhotoreceptorsPigmentsPreventive measureProspective StudiesProspective cohortRecommendationRecoveryResearchRetinaRetinalRiskRisk MarkerRoleSamplingSerumSpeedSupplementationTechniquesTestingThickThinnessTimeVisionVisitVisual AcuityWomanWomen&aposs Healthage relatedcohortcostdensitydesignfollow-upfovea centralisgenetic risk factorhealth datahigh riskimprovedlifestyle datamaculameso-zeaxanthinmiddle agemodifiable riskmortalityneurosensorynutrition related geneticsprocessing speedprospectiveprotective effectpublic health relevanceretinal nerve fiber layerscreeningsecondary analysissoundvisual processingzeaxanthin
项目摘要
DESCRIPTION (provided by applicant): The purpose of this proposal is to evaluate macular pigment (MP) levels as a modifiable risk marker for the development of age-related macular degeneration (AMD), and more generalized loss of neural retina and vision function with age. Some previous evidence suggests that MP, comprised of the dietary carotenoids lutein, zeaxanthin and meso-zeaxanthin, declines with age, and that preserving MP might help reduce risk for developing eye diseases and/or vision loss which become more common as we age. This has not been previously evaluated in large longitudinal studies. MP optical density (MPOD) can be simply and non-invasively measured. Therefore, MPOD assessment might be useful in screening to identify individuals, in middle-age, who are at higher risk for age-related vision los. Devices to assess MPOD are already adapted for clinical use, but evidence addressing longitudinal relationships of MPOD to AMD and vision loss is needed to make recommendations about their appropriate use. If MPOD predicts AMD and/or age- or disease-related vision loss, then early assessment would permit the targeting of individuals for testing a variety of preventive measures to lower risk, including those which would increase macular pigment. Evidence to address the gap in longitudinal data can be obtained at low cost by conducting a prospective follow-up study in the Carotenoids in Age-Related Eye Disease Study (CAREDS) cohort. MPOD, fundus photographs to assess AMD, and visual acuity measures were previously obtained in 1,791 women in 2001-2004. Annual follow-up of this cohort, in the Women's Health Initiative, assures low loss to follow up, documents mortality and new chronic diseases (including common age-related eye diseases), and provides extensive nutritional, genetic, lifestyle, and health data. Follow-up visits thirteen years later will be conducted to provide a second set of fundus photographs to document the relationships of MPOD to AMD incidence and/or progression. Second, MPOD at baseline will also be studied in relation to measures of structural and functional aging at follow-up. Structural measures include new measures of the thickness of the retina, across several layers and regions, using spectral domain optical coherence tomography (SD-OCT). Functional measures include the loss of visual acuity between baseline and follow-up, and additional secondary measures obtained at follow-up. Third, measures of MPOD levels at follow-up will be obtained to permit the first direct longitudinal estimate of MPOD declines with age, and to provide an opportunity to explore whether average age-related declines are lower in women with higher initial MPOD, and in women with higher intakes of lutein and zeaxanthin, between baseline and follow-up. The proposed research will constitute the largest and longest extant investigation of relationships of macular pigment to aging, age-related vision loss, and AMD, thereby advancing knowledge needed to understand the role of carotenoids in preserving vision with age and informing clinical guidelines.
描述(由申请人提供):本提案的目的是评估黄斑色素(MP)水平,作为年龄相关性黄斑变性(AMD)发展的可修改风险标记,以及更广泛的神经视网膜和视觉功能丧失。先前的一些证据表明,由膳食类胡萝卜素叶黄素、玉米黄质和内消旋玉米黄质组成的 MP 会随着年龄的增长而下降,而保留 MP 可能有助于降低患眼病的风险。和/或视力丧失随着年龄的增长而变得更加普遍,这在之前的大型纵向研究中尚未得到评估,因此,MPOD 评估可能有助于筛查和识别。与年龄相关的视力丧失风险较高的中年人用于评估 MPOD 的设备已经适合临床使用,但需要证明 MPOD 与 AMD 和视力丧失的纵向关系的证据来提出适当的建议。如果 MPOD 预测 AMD。和/或与年龄或疾病相关的视力丧失,那么早期评估将允许针对个体测试各种预防措施以降低风险,包括那些会增加黄斑色素的措施,可以提供解决纵向数据差距的证据。通过在类胡萝卜素与年龄相关的眼病研究 (CAREDS) 队列中进行前瞻性随访研究,以低成本获得了评估 AMD 的眼底照片,以及之前对 1,791 名女性进行的视力测量。 2001-2004 年,在妇女健康倡议中对这一群体进行年度随访,确保随访损失率低,记录死亡率和新发慢性疾病(包括常见的生活方式与年龄有关的眼病),并提供广泛的营养、遗传、遗传信息。十三年后的随访将提供第二组眼底照片,以记录 MPOD 与 AMD 发病率和/或进展的关系。其次,还将研究基线时的 MPOD 与测量的关系。结构和功能老化结构测量包括使用谱域光学相干断层扫描(SD-OCT)对视网膜厚度进行新测量,功能测量包括基线和随访之间的视力丧失。第三,将获得随访时 MPOD 水平的测量,以便对 MPOD 随着年龄的下降进行首次直接纵向估计,并提供一个机会来探讨平均与年龄相关的下降是否存在。在基线和随访期间,初始 MPOD 较高的女性以及叶黄素和玉米黄质摄入量较高的女性中,黄斑色素与衰老、年龄相关性视力丧失之间的关系较低。和 AMD,推进了解类胡萝卜素的作用所需的知识,从而随着年龄的增长保持视力并为临床指南提供信息。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BARBARA A BLODI其他文献
BARBARA A BLODI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BARBARA A BLODI', 18)}}的其他基金
Intravitreal Corticosteroid for Macular Edema Study
玻璃体内皮质类固醇治疗黄斑水肿研究
- 批准号:
6556115 - 财政年份:2003
- 资助金额:
$ 96.33万 - 项目类别:
Intravitreal Corticosteroid for Macular Edema Study
玻璃体内皮质类固醇治疗黄斑水肿研究
- 批准号:
6895738 - 财政年份:2003
- 资助金额:
$ 96.33万 - 项目类别:
相似国自然基金
ALKBH5通过SHP-1调控视网膜色素上皮细胞铁死亡在年龄相关性黄斑变性中的作用机制研究
- 批准号:82301213
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
何氏养巢方通过SIRT3打破年龄相关性“ROS恶性循环”改善高龄小鼠卵母细胞IVM及质量的机制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
一氧化碳释放分子-3(CORM-3)通过抑制晶状体上皮细胞凋亡对年龄相关性白内障治疗作用机制的研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
菊花多元组分通过调控肠道菌群结构及内源性代谢改善年龄相关性黄斑变性作用机制研究
- 批准号:
- 批准年份:2021
- 资助金额:55 万元
- 项目类别:面上项目
HTRA1通过调控RPE细胞脂质代谢介导年龄相关性黄斑变性中玻璃膜疣形成的机制研究
- 批准号:82000915
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:青年科学基金项目
相似海外基金
Cafe Move: A Novel Program for Prevention of Age-Related Physical Frailty
Cafe Move:预防与年龄相关的身体虚弱的新计划
- 批准号:
10861960 - 财政年份:2023
- 资助金额:
$ 96.33万 - 项目类别:
HIV Clinic-based Screening for Geriatric Syndromes in Older Adults with HIV
基于艾滋病毒临床的艾滋病毒感染者老年综合症筛查
- 批准号:
10761940 - 财政年份:2023
- 资助金额:
$ 96.33万 - 项目类别:
The impact of Medicaid expansion on the rural mortality penalty in the United States
医疗补助扩大对美国农村死亡率的影响
- 批准号:
10726695 - 财政年份:2023
- 资助金额:
$ 96.33万 - 项目类别:
A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors
对免疫检查点抑制剂有持久反应的晚期癌症患者的多机构生存研究
- 批准号:
10714336 - 财政年份:2023
- 资助金额:
$ 96.33万 - 项目类别:
Share plus: Continuous Glucose Monitoring with Data Sharing in Older Adults with T1D and Their Care Partners
分享加:患有 T1D 的老年人及其护理伙伴的持续血糖监测和数据共享
- 批准号:
10660793 - 财政年份:2023
- 资助金额:
$ 96.33万 - 项目类别: